OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Cost-effectiveness analysis of anlotinib as a third-line or further treatment for advanced non-small cell lung cancer in China
Qiuyan Zhu, Ronghua Ni, Xin–Yuan Guan
Translational Lung Cancer Research (2023) Vol. 12, Iss. 8, pp. 1782-1789
Open Access | Times Cited: 5
Qiuyan Zhu, Ronghua Ni, Xin–Yuan Guan
Translational Lung Cancer Research (2023) Vol. 12, Iss. 8, pp. 1782-1789
Open Access | Times Cited: 5
Showing 5 citing articles:
Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer
Qi Cai, Shuhui You, Jinglong Huang, et al.
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access
Qi Cai, Shuhui You, Jinglong Huang, et al.
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access
Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China
Chunyan Yan, Zhengxiong Li, Jiayan Li, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Chunyan Yan, Zhengxiong Li, Jiayan Li, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Injectable hydrogel for controlled anlotinib delivery and enhanced anti-tumor therapy in non-small cell lung cancer
Hongwei Lan, Yuming Zhang, Zuoxiang Dong, et al.
Materials & Design (2025), pp. 114103-114103
Open Access
Hongwei Lan, Yuming Zhang, Zuoxiang Dong, et al.
Materials & Design (2025), pp. 114103-114103
Open Access
Etoposide soft capsule combined with anlotinib in the third-line treatment of advanced non-small cell lung cancer: a retrospective cohort study
Yijun Dai, Yanru Qiu, Jianguang Lin, et al.
Journal of Thoracic Disease (2023) Vol. 15, Iss. 10, pp. 5680-5688
Open Access | Times Cited: 1
Yijun Dai, Yanru Qiu, Jianguang Lin, et al.
Journal of Thoracic Disease (2023) Vol. 15, Iss. 10, pp. 5680-5688
Open Access | Times Cited: 1
Cost-effectiveness of Kang Ai injection plus chemotherapy vs. Shenqi Fuzheng injection plus chemotherapy in the first-line treatment of advanced non-small cell lung cancer
Junjie Zhu, Lei Tian
Frontiers in Medicine (2024) Vol. 11
Open Access
Junjie Zhu, Lei Tian
Frontiers in Medicine (2024) Vol. 11
Open Access
TQB2450 with or without anlotinib as maintenance treatment in subjects with locally advanced/unresectable non-small cell lung cancer that have not progressed after prior concurrent/sequential chemoradiotherapy (R-ALPS): study protocol for a randomized, double-blind, placebo-controlled, multicenter phase III trial
Baiqiang Dong, Long Chen, Qingsong Pang, et al.
Translational Lung Cancer Research (2024) Vol. 13, Iss. 10, pp. 2828-2837
Open Access
Baiqiang Dong, Long Chen, Qingsong Pang, et al.
Translational Lung Cancer Research (2024) Vol. 13, Iss. 10, pp. 2828-2837
Open Access
